Navigation Links
Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation
Date:10/2/2008

asts and projections about the industry and markets in which Dyax competes. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors which may affect the expected benefits of Dyax's collaboration with Athera and the prospects for development of antibodies to phosphorylcholine include the risks that: products from this collaboration may not show therapeutic effect or an acceptable safety profile in clinical trials or could take a significantly longer time to gain regulatory approval than Dyax expects or may never gain approval; products developed in this collaboration may not gain market acceptance; others may develop products superior to those being developed in this collaboration; Dyax is dependent on the expertise, effort, priorities and contractual obligations of Athera in the development of products arising out of this collaboration; Dyax and Athera may not be able to obtain and maintain intellectual property protection for the products of this collaboration; and other risk factors described or referred to in Dyax's most recent Annual Report on Form 10-K and other periodic reports filed with the Securities and Exchange Commission. Dyax cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Dyax undertakes no obligations to update or revise these statements, except as may be required by law. Dyax specifically disclaims responsibility for information describing Athera and its business other than the license with Dyax.

Dyax and the Dyax logo are the registered trademarks of Dyax Corp.

About Athera Biotechnologies

Athera Biotechnologies AB develops novel products for risk assessment
'/>"/>

SOURCE Athera Biotechnologies
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
2. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... noviembre de 2014  BioClinica®, Inc., un proveedor ... tecnologías eClinical, ha indicado un aumento de la ... el seguimiento basado en el riesgo en los ... del seguimiento basado en el riesgo más allá ... seguimiento o cambio de los métodos de seguimiento. ...
(Date:11/22/2014)... , Nov. 21, 2014 MEDITE Group acquired by ... months and the 3 rd quarter sales ended September ... was $448,000 for the nine months ended September 2014 and ... though our 3 rd quarter is usually a seasonable ... from July into September for many countries worldwide, we are ...
(Date:11/22/2014)... 21, 2014 Many power shifts are ... influence of patients in the biopharmaceutical market is ... more than ever, understanding how to effectively acquire, ... is essential. According to recent ... companies spent about two-thirds of their patient-focused dollars ...
Breaking Medicine Technology:El 'seguimiento inteligente' consigue un excelente momento 2El 'seguimiento inteligente' consigue un excelente momento 3CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 2CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 3New Report Details Importance of Adopting a "Patient Journey" Framework in Marketing 2
(Date:11/24/2014)... Diego, California (PRWEB) November 24, 2014 Dr. ... San Diego Fertility Center, recently appeared on NBC to discuss ... option. Egg freezing has been trending in the news recently, ... this expensive procedure for women. , “[The companies] ... women who are on a career hot path.” Says Dr. ...
(Date:11/23/2014)... For the coming special Friday, Tidebuy, a famous wedding ... for many products, especially the beautiful colored wedding dresses ... with amazing discounts, up to 90% off. Don’t hesitate ... easy to buy colored wedding dresses in different sizes ... famous for delicate craftsmanship, elegant style and perfect lines. ...
(Date:11/23/2014)... NY (PRWEB) November 23, 2014 ... allege heart attacks, strokes, deep vein thrombosis and ... in a federal multidistrict litigation (MDL) underway in ... reports. , Court documents updated on November ... Litigation (JPML) show the filing of 259 lawsuits ...
(Date:11/23/2014)... This evaluation provides a basic conclusion ... and manufacturing technological innovation. Then, the evaluation investigates ... in information. In this part, the evaluation provides ... and 2009-2014 market shares for each company. Through ... and Chinese suppliers finish market of Femoral Occurs ...
(Date:11/23/2014)... 2014 AngelWeddingDress.com has recently ... selection of beach wedding dresses. “If you are looking ... AngelWeddingDress.com as soon as possible. Here you can enjoy ... manager says. , Holding a big marriage ceremony is ... a beautiful beach wedding dress is uppermost priority. Ophelia, ...
Breaking Medicine News(10 mins):Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 2Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 3Health News:Beautiful Wedding Dresses Available at Popular B2C Company Tidebuy 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 3Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 2Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 3Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 4Health News:Beach Wedding Dresses Added to Outstanding Online Dress Company AngelWeddingDress.com 2
... Biologist Lee Ligon has found a previously unknown connection ... tissue. The results provide new information on the earliest ... published March 7, 2012, in the journal PLoS ... Cell-Cell Adhesion between Breast Cancer Epithelial Cells and Fibroblasts." ...
... Loyola University Chicago Stritch School of Medicine study has revealed ... enables cancer cells to establish tumors in distant parts of ... new drugs to prevent breast cancer and other cancers from ... PhD and colleagues is published in the March 16 ...
... new study by University of Kentucky researchers provides insight ... commonly known as triple-negative breast cancer. This cancer is ... occurs at women at a younger age. Tumor ... migration and reduces adhesion between cells to spread to ...
... philosophers will come together at a special conference next month ... Among the questions for discussion will be: Is the ... citizens to make them fit for work? Or is it ... ,Civil Association, is the spring conference of the Think About ...
... is available in German . Every cell ... separates the distinct internal environment of the cell from the ... as plasma membrane, disturbs the cellular functions and may lead ... tears many little holes into the plasma membranes of the ...
... large international study indicates that anti-inflammatory drugs may become ... disease (CHD), the leading global cause of death. In ... heart disease, the researchers used the Cardiochip, a gene ... researcher in the Center for Applied Genomics at The ...
Cached Medicine News:Health News:Biologists uncover surprising connection between breast cancer cells and surrounding tissue 2Health News:How cancer cells start new tumor sites 2Health News:New study shows promise for developing new treatments for breast cancer 2Health News:Conference explores ethical dimension of NHS 2Health News:How muscle cells seal their membranes 2Health News:Gene chip invented by CHOP scientist pinpoints new target to prevent heart disease 2
The Elisa test is used for the detection and semi-quantitative determination of IgG, antibodies to myeloperoxidase in human sera as an aid to the diagnosis is of microscopic polyangiitis....
... this Enzyme ImmunoAssay (EIA) is as follows: ... on a 96 well microtiter plate. After ... the trapped molecule is covalently linked to ... After washing and denaturing treatment, Angiotensin II ...
... a solid phase two-site enzyme immunoassay. ... sandwich technique in which two monoclonal ... determinants on the insulin molecule. During ... with peroxidase-conjugated anti-insulin antibodies and anti-insulin ...
... SAS RSV antigen test is ... for the presumptive qualitative detection ... from nasopharyngeal specimens in neonatal ... 15 minute test has a ...
Medicine Products: